These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21926632)

  • 1. Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals.
    Jackson A; Watson V; Back D; Khoo S; Liptrott N; Egan D; Gedela K; Higgs C; Abbas R; Gazzard B; Boffito M
    J Acquir Immune Defic Syndr; 2011 Dec; 58(5):450-7. PubMed ID: 21926632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
    Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.
    Jackson A; Moyle G; Dickinson L; Back D; Khoo S; Taylor J; Gedela K; Abongomera G; Gazzard B; Boffito M
    Antivir Ther; 2012; 17(1):19-24. PubMed ID: 22267465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients.
    Martínez-Rebollar M; Muñoz A; Pérez I; Hidalgo S; Brunet M; Laguno M; González A; Calvo M; Loncà M; Blanco JL; Martínez E; Gatell JM; Mallolas J
    Ther Drug Monit; 2013 Aug; 35(4):552-6. PubMed ID: 23851911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of darunavir at 900 milligrams and ritonavir at 100 milligrams once daily when coadministered with efavirenz at 600 milligrams once daily in healthy volunteers.
    Soon GH; Shen P; Yong EL; Pham P; Flexner C; Lee L
    Antimicrob Agents Chemother; 2010 Jul; 54(7):2775-80. PubMed ID: 20385850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.
    Dailly E; Allavena C; Bouquié R; Deslandes G; Raffi F; Jolliet P
    AIDS Res Hum Retroviruses; 2013 Jan; 29(1):42-6. PubMed ID: 23148588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients.
    Cattaneo D; Gervasoni C; Cozzi V; Baldelli S; Fucile S; Meraviglia P; Landonio S; Boreggio G; Rizzardini G; Clementi E
    Pharmacol Res; 2012 Feb; 65(2):198-203. PubMed ID: 21958880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infection.
    Calza L; Colangeli V; Magistrelli E; Bussini L; Conti M; Ramazzotti E; Mancini R; Viale P
    HIV Med; 2017 Aug; 18(7):474-481. PubMed ID: 28116848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.
    Calza L; Danese I; Colangeli V; Manfredi R; Magistrelli E; Verucchi G; Conti M; Motta R; Viale P
    Infect Dis (Lond); 2015 Sep; 47(9):625-36. PubMed ID: 25875396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients.
    Ter Heine R; Mulder JW; van Gorp EC; Wagenaar JF; Beijnen JH; Huitema AD
    Br J Clin Pharmacol; 2010 May; 69(5):475-83. PubMed ID: 20573083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Herb-drug interaction between Echinacea purpurea and darunavir-ritonavir in HIV-infected patients.
    Moltó J; Valle M; Miranda C; Cedeño S; Negredo E; Barbanoj MJ; Clotet B
    Antimicrob Agents Chemother; 2011 Jan; 55(1):326-30. PubMed ID: 21078942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients.
    Moltó J; Valle M; Santos JR; Mothe B; Miranda C; Cedeño S; Negredo E; Yritia M; Videla S; Barbanoj MJ; Clotet B
    Antivir Ther; 2010; 15(2):219-25. PubMed ID: 20386077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of a significant drug interaction between raltegravir and tenofovir.
    Wenning LA; Friedman EJ; Kost JT; Breidinger SA; Stek JE; Lasseter KC; Gottesdiener KM; Chen J; Teppler H; Wagner JA; Stone JA; Iwamoto M
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3253-8. PubMed ID: 18625763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).
    Taiwo B; Zheng L; Gallien S; Matining RM; Kuritzkes DR; Wilson CC; Berzins BI; Acosta EP; Bastow B; Kim PS; Eron JJ;
    AIDS; 2011 Nov; 25(17):2113-22. PubMed ID: 21857490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
    Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P
    HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of milk thistle on the pharmacokinetics of darunavir-ritonavir in HIV-infected patients.
    Moltó J; Valle M; Miranda C; Cedeño S; Negredo E; Clotet B
    Antimicrob Agents Chemother; 2012 Jun; 56(6):2837-41. PubMed ID: 22430963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.
    Arab-Alameddine M; Lubomirov R; Fayet-Mello A; Aouri M; Rotger M; Buclin T; Widmer N; Gatri M; Ledergerber B; Rentsch K; Cavassini M; Panchaud A; Guidi M; Telenti A; Décosterd LA; Csajka C;
    J Antimicrob Chemother; 2014 Sep; 69(9):2489-98. PubMed ID: 24821595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction.
    Fabbiani M; Di Giambenedetto S; Ragazzoni E; D'Ettorre G; Parruti G; Prosperi M; Bracciale L; Cauda R; Navarra P; De Luca A
    Pharmacol Res; 2011 Mar; 63(3):249-53. PubMed ID: 21130167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients.
    Moltó J; Valle M; Back D; Cedeño S; Watson V; Liptrott N; Egan D; Miranda C; Barbanoj MJ; Clotet B
    Antimicrob Agents Chemother; 2011 Jan; 55(1):72-5. PubMed ID: 20937791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients.
    Barrail-Tran A; Yazdanpanah Y; Goldwirt L; Chêne G; Colin C; Piketty C; Bollens D; Katlama C; Descamps D; Molina JM; Fagard C; Taburet AM;
    AIDS; 2010 Oct; 24(16):2581-3. PubMed ID: 20960678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.